Navigation Links
Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis

OWL Genomics, biotechnological company, has presented at the CIC bioGUNE hold at the Bizkaia Technological Park (Derio), the first DNA chip concerning diagnosis and prognosis of non-alcoholic steatohepatitis (NASH), allowing the discrimination between normal, steatosis and NASH predisposed subjects.

Non alcoholic steatohepatitis is a progressive disease of the liver of unknown etiology, characterized histologically by fatty acid accumulation, hepatocyte damage and inflammation resembling alcoholic hepatitis. NASH is a critical stage in the process that spans from hepatic steatosis to cirrhosis and hepatocarcinoma. NASH is one of the most common causes of elevated aminotransfereases in patients referred for evaluation to hepatologists. Obesity and type-2 diabetes are associated to NASH. Since the prevalence of these diseases is increasing, the prevalence of NASH is also expected to increase and therefore, this disease has become an emerging public issue in United States as well as in other developed countries

The HEPATOCHIP presented at the mentioned forum, has been developed in collaboration with the Hepatology Services of the Clinic Hospital in Barcelona and Príncipe de Asturias Hospital in Alcalá de Henares (Madrid). This chip analyses the co-expression of 85 genes that are related with NASH and is about to be validated in collaboration with the Hepatology Service of Gregorio Marañón Hospital (Madrid).

This HEPATOCHIP method determines the co-expression of genes in the liver tissue sample, providing monitoring treatment regimens to check progression/regression of these liver pathologies.

This HEPATOCHIP can be used as a prognostic tool for NASH-predisposed patients, to make possible more finely tuned diagnosis of this disease and allow healthcare professionals to tailor treatment to individual patients' needs. This chip also assess the efficacy of non-alcoholic steatohepatitis treatment by determining progression or regression of NAS H in patients before, during, and NASH treatment.

###

OWL Genomics, a biotech company focused on providing leading-edge applications in human health with innovative and pioneer technologies within the international scientific community, provides the first product in early diagnosis and therapeutic targets in hepatic diseases.

OWL Genomics is devoted to research into the diagnosis and prevention of liver diseases, through the combination of its state-of-the-art technology and experienced and dedicated personnel.


'"/>

Source:OwlGenomics


Related biology news :

1. New comparative toxicogenomics database
2. Measuring the impact of post-genomics on Mediterranean populations
3. Enlisting genomics to understand flu evolution
4. Drawing with DNA: Bioart illuminates genomics
5. Study reveals genomics of inflammation from severe injury
6. NIH launches comprehensive effort to explore cancer genomics
7. Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy
8. Ticks, flukes, and genomics: Emerging pathogens revealed
9. UC San Diego partners with Venter Institute to build marine microbial genomics cyberinfrastructure
10. Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease
11. Large-scale genomics project will hunt genes behind common childhood diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/22/2016)... 22, 2016 According to the new market research ... Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and ... the market is expected to grow from USD 10.74 Billion in 2015 ... between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)...  AIC announces that it has just released a new white paper authored by ... plus high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can ...
(Date:11/14/2016)... 14, 2016  Based on its recent ... & Sullivan recognizes FST Biometrics with the ... Visionary Innovation Leadership. FST Biometrics emerged as ... market by pioneering In Motion Identification (IMID) ... seamless, and non-invasive verification. This patented solution ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse® IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
(Date:12/8/2016)... Dec. 8, 2016 Eurofins announces the appointment of ... of Eurofins Scientific Inc. (ESI). Mr. Murray will ... professional and entrepreneurial experience in leading international business teams. As the ... testing market to uphold Eurofins, status as the global leader in ... , ...
(Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., ... development of the next generation neuro-thrombectomy system for the ... of Tudor G. Jovin, MD to join its Scientific ... as a strategic network of scientific and clinical experts ... development of the ANCD BRAIN ® to its ...
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
Breaking Biology Technology: